CN101299934B - 用于促进追赶生长的营养制剂 - Google Patents
用于促进追赶生长的营养制剂 Download PDFInfo
- Publication number
- CN101299934B CN101299934B CN2006800413205A CN200680041320A CN101299934B CN 101299934 B CN101299934 B CN 101299934B CN 2006800413205 A CN2006800413205 A CN 2006800413205A CN 200680041320 A CN200680041320 A CN 200680041320A CN 101299934 B CN101299934 B CN 101299934B
- Authority
- CN
- China
- Prior art keywords
- described application
- benefit
- fiber
- given birth
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 20
- 238000009472 formulation Methods 0.000 title abstract description 7
- 230000001737 promoting effect Effects 0.000 title description 2
- 239000000835 fiber Substances 0.000 claims abstract description 24
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 239000006041 probiotic Substances 0.000 claims abstract description 14
- 235000018291 probiotics Nutrition 0.000 claims abstract description 14
- 230000000529 probiotic effect Effects 0.000 claims abstract description 13
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 46
- 230000008901 benefit Effects 0.000 claims description 24
- 229920001202 Inulin Polymers 0.000 claims description 15
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 15
- 229940029339 inulin Drugs 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 8
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 208000034657 Convalescence Diseases 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000032696 parturition Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 235000013406 prebiotics Nutrition 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000003340 mental effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 description 22
- 230000037213 diet Effects 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000020940 control diet Nutrition 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000012371 Aseptic Filling Methods 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UIKHKLFBHLPAPO-UHFFFAOYSA-N 2,3-diacetyl-2,3-dihydroxybutanedioic acid Chemical compound CC(=O)C(O)(C(O)=O)C(O)(C(C)=O)C(O)=O UIKHKLFBHLPAPO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种包含n3长链多不饱和脂肪酸(LC-PUFA)、益生纤维和益生菌株的营养制剂,其成分以协同方式一起起作用来促进其生长由于遭受生理或心理应激曾被阻滞的幼年哺乳动物的追赶生长。
Description
技术领域
本申请涉及用于促进因为遭受生理或心理应激而致使生长被延迟的年幼哺乳动物的追赶生长(catch-up growth)的制剂以及该类制剂的应用。本发明特别是涉及包含用于促进追赶生长的成分的协同组合。
背景技术
多年来,人们已经意识到,不管是身体上的疾病或损伤还是心理创伤,遭受应激的幼年哺乳动物的生长常常被阻断。如果幼年哺乳动物迅速恢复并且可以获得足够的营养,则可以补偿在应激期间应当进行的生长,并且这种突然进发的生长被称为“追赶生长”。但是,并不是总会发生这种生长。例如,幼年哺乳动物在疾病或创伤期间和在疾病刚刚痊愈后都可能患厌食症,因此,摄食可能受限。在一些严重的情况中,动物可能永远不能达到其没有遭受应激时将能达到的身高。
在包括人在内的幼年(从婴儿期至其仍然进行生长的整个生命时期)哺乳动物中可观察到这种现象。虽然希望能确保补偿生理或心理应激期间降低的生长,但是,追赶生长不能过度也是很重要的,这是因为有迹象表明十分迅速和/或十分过度的追赶生长,特别是婴儿期的追赶生长可能伴有未来肥胖的风险。
因此,本发明的目的是提供一种适于促进曾遭受生理或心理应激的幼年哺乳动物最佳的追赶生长的制剂。
本发明的概述
在导致本发明的一些研究中,本发明的发明人出乎意料地观察到服用特定的成分组合可促进曾遭受应激的幼年哺乳动物的追赶生长。
因此,第一方面,本发明提供了一种用于促进追赶生长的营养制剂,其包含含有脂肪酸的脂类源、含量为组合物中脂肪酸的至少0.01%的n3长链多不饱和脂肪酸(LC-PUFA)、数量至少为0.001g/g制剂的益生纤维和数量为103-1011cfu/g制剂的益生菌株。
在第二方面,本发明提供了n3长链多不饱和脂肪酸(LC-PUFA)、益生纤维和益生菌株用于制备促进患病和恢复期幼年哺乳动物的追赶生长的营养制剂或药物应用。
本发明进一步提供了一种促进患病或恢复期幼年哺乳动物的追赶生长的方法,其包括给需要其的幼年哺乳动物施用治疗有效量的包含n3LC-PUFA、益生纤维和益生菌株的制剂。
本发明的一个优点是提供了促进追赶生长的可能性,其不使用合成激素,而是使用协同的食品级成分的组合。另外,经受应激的幼年哺乳动物常常患有厌食症并且不愿意或不能消耗大量卡路里;本发明的一个优点是在不增加卡路里摄入量、具有平衡的无脂肪和脂肪体重以及不会促进肥胖的情况下提供了促进追赶生长的机会。
附图说明
图1表示了分娩后天数(PND)为15-21天的接受不同饮食的6组大鼠的体重评估。
图2表示从PND 21-36天,图1中所示的相同大鼠组的体重评估。
图3表示从PND 21-36天,相同大鼠组的摄食情况。
图4表示在PND 36天,六组大鼠以g/cm2为单位的体重指数。
图5表示在PND 36天,六组大鼠以g为单位的附睾(epididimal)和腹膜后脂肪垫重量。
本发明的详细描述
在本说明书中,下面的术语具有以下给出的含义:
“益生菌株”指的是活的微生物饲料添加物,其通过改善宿主动物的肠内微生物平衡而对宿主动物产生有益影响(得自“人和动物中的益生菌(Probiotics in Man and Animals)”,J.Appl Bacteriol.66:365-378,1989)。
“益生元”指的是通过选择性刺激结肠中一种或有限数目细菌的生长和/或活性来对宿主产生有益影响,从而改善宿主健康的不易消化的食物成分(得自“人结肠微生物区的饮食调节:引入益生元的概念(DietaryModulation of the Human Colonic Microbiota:Introducing the Concept ofPrebiotics)”,J.Nutr.125:1401-1412,1995)。
“幼年哺乳动物”指的是从出生至所涉及种属哺乳动物达到其完美身高的年龄的包括人和伴侣动物在内的任何哺乳动物。
所述益生菌株优选地是乳酸杆菌属或双岐杆菌属菌株。适宜的乳酸杆菌属菌株包括得自Valio OY,芬兰的鼠李糖乳酸杆菌(Lactobacillusrhamnosus)ATCC 53103和副干酪乳杆菌(Lactobacillus paracasei)CNCMI-2116,特别优选后者。适宜的双岐杆菌属菌株包括得自Morinaga,日本的长双岐杆菌BB536、得自Christian Hansen of Denmark的商标为Bb 12的乳双歧杆菌的菌株和乳双歧杆菌CNCM 1-3446。可以使用菌株的组合,特别优选乳酸杆菌属和双岐杆菌属的组合。所选择的菌株或菌株组合可以以通过冷冻干燥或喷雾干燥获得的粉末的形式被包括在所述制剂中。或者,该营养制剂还可以包含可发酵的食品如奶或谷类并且可以用所述益生菌株来发酵该食品。
益生纤维可选自低聚果糖、低聚半乳糖、低聚唾液糖(sialo-oligosaccharide)、低聚木糖(xylo-oligosaccharide)、菊粉、阿拉伯胶、瓜尔胶、抗性淀粉(resistant starch)、得自奶的寡糖以及其混合物。优选的益生纤维是低聚果糖、菊粉、阿拉伯胶和低聚半乳糖,特别是70至95%低聚半乳糖和30至5%低聚果糖和40至60%阿拉伯胶、30至40%低聚果糖和10至20%菊粉的混合物。适宜的低聚半乳糖是Borculo DomoIngredients以商标Vivinal GOS 10销售的物质。适宜的低聚果糖是OraftiS.A以商标Raftilose P95销售的物质。适宜的菊粉是由Orafti S.A以商标Raftiline HP销售的物质。适宜的阿拉伯胶是CNI以商标FiberGum P销售的物质。益生纤维或纤维混合物的存在总量优选为0.02-0.05g/g制剂。
该制剂包含至少一种n-3LC-PUFA如C20或C22n-3脂肪酸。该C20或C22n-3LC-PUFA的存在量优选为所述制剂中所有脂肪酸重量的至少0.1%。n-3LC-PUFA优选是二十二碳六烯酸(DHA,C22:6,n-3)。
所述制剂还优选地包含n-6多不饱和脂肪酸如C20或C22n-6脂肪酸。适宜的n-6LC-PUFA是花生四烯酸(AA,C20:4n-6)。C20或C22n-6LC-PUFA的存在量优选为该制剂中所有脂肪酸重量的至少0.1%。
n6∶n3的比例优选为1∶2至8∶1,更优选为4∶1至8∶1。LC-PUFA的来源可以是例如卵脂类、真菌油、低EPA鱼油或海藻油(algal oil)。
所述制剂可以以营养添加物的形式存在或者其可以提供全部营养。用于本发明营养制剂的适宜基质的实例有奶、酸奶、凝乳、乳酪、发酵乳和乳制品、以发酵的谷类为基础的产品、以奶为基础的粉末、用于口服和管饲的婴儿配方和组合物。
在一个优选的实施方案中,本发明提供了一种婴儿配方或儿科营养制剂。除上述协同的成分组合外,其还可以包含蛋白源和/或碳水化合物源。
蛋白源可以是任何适宜的饮食蛋白;例如动物蛋白(如乳蛋白、肉蛋白、卵蛋白)、植物蛋白(如大豆、小麦、水稻或豌豆蛋白)、游离氨基酸混合物、或其组合。特别优选乳蛋白如酪蛋白和乳清。在儿科制剂一个优选的实施方案中,蛋白源提供了该组合物能量的7至14%。
对于儿科制剂而言,脂质源优选地提供了该制剂能量的30%至50%。组成脂质源的脂类可以是任何适宜的脂肪或脂肪混合物。植物脂肪是特别适宜的;例如豆油、棕榈油、椰子油、红花油、向日葵油、玉米油、芸苔油、卵磷脂等。如果需要的话,也可以加入动物脂肪如乳脂。脂肪源优选包含至少15%中链甘油三酯类并且该脂肪酸的组成是20至40%的饱和脂肪酸、45至60%的单不饱和脂肪酸和10至25%的多不饱和脂肪酸。
如果该儿科制剂包含碳水化合物源,则该碳水化合物源优选提供了该制剂能量的40%至60%。可以使用任何适宜的碳水化合物或碳水化合物混合物,例如蔗糖、乳糖、葡萄糖、果糖、玉米糖浆固体和麦芽糖糊精。
可以以常规方式在该制剂中包含适宜的维生素和矿物质以满足适宜的指导。如果需要的话,可以向该制剂中混入一种或多种食品级乳化剂,例如单-二甘油酸酯的二乙酰基-酒石酸酯、卵磷脂和单-和二-甘油酸酯。类似地,还可包括适宜的盐类和稳定剂。
该制剂优选进行肠道给药,例如以用于用水重构的粉末的形式进行给药。被重构的制剂可以被口服给药或用鼻胃管来进行给药。其可以以任何适宜的方式来进行制备,例如可以通过将饮食性蛋白源、碳水化合物源和脂肪源以适宜的比例掺合到一起来进行制备。如果需要的话,在该掺合物中可以包含乳化剂。可以在这时加入维生素和矿物质,但是通常在稍后加入以避免热降解。可以在掺合前,将任何亲脂性维生素、乳化剂等溶解到脂肪源中。然后,可以混入水(优选已经进行过反渗透的水)从而形成一种液体混合物。水的温度适宜地为约50℃至80℃以帮助所述成分进行分散。可以使用可通过商业途径获得的液化剂来形成所述液体混合物。然后,将该液体混合物匀化;例如分两步进行匀化。
然后,可以对该液体混合物进行热处理以降低细菌负载量。例如,可以在约5秒至5分钟内将该液体混合物迅速加热至约80℃至约150℃。其可以通过蒸汽喷射、高压灭菌器或热交换器;例如板式热交换器来进行。然后,可以将该液体混合物冷却至约60℃至约85℃;例如通过瞬时冷却来进行冷却。然后,可以将该液体混合物再次匀化;例如分两个阶段进行匀化,在第一阶段,在约7MPa至约40MPa下进行匀化,在第二阶段,在约2MPa至约14MPa下进行匀化。然后,为了加入任何热敏感的组分,如维生素和矿物质,可以将该匀化的混合物进一步冷却。这时,适宜地使该匀化组合物的pH和固体含量符合标准。
将该进行了匀化的混合物转移到适宜的干燥装置如喷雾干燥器或冷冻干燥器中并将其转化成粉末。该粉末应当具有低于约5%重量的水分含量。这时,可以通过干法混合方便地加入所述的益生菌株。
如果希望制备一种液体制剂,则优选将该匀化的混合物无菌填充到适宜的容器中。容器的无菌填充可以通过将被匀化的混合物预热(例如至约75至85℃),然后向该匀化混合物中注射蒸汽以将其温度升至约140至160℃;例如约150℃来进行。然后,将被匀化的混合物冷却(例如通过瞬时冷却)至约75至85℃。然后,将该被匀化的混合物匀化,进一步将其冷却至约室温并将其填充到容器中。用于进行这种性质的无菌填充的适宜装置可以通过商业途径获得。液体配方可以为具有约10至约14%重量固体含量的即可使用的配方形式或者可以为浓缩物形式;其固体含量通常为约20至约26%重量。可以向该液体配方中加入矫味剂。在液体配方的情况中,所述益生菌株优选地被独立包装供给,用于在该液体制剂临被消耗前混合。
喂给幼年哺乳动物所需的制剂数量将根据诸如患者的情况、体重和年龄、以及该制剂是否是唯一的营养源之类的因素来进行变化。一般而言,给予足够的制剂以为患者提供1至4g/kg体重/天的补充有如上所示数量的本发明成分的蛋白。如果该营养制剂被用作其它食品的添加物,则每天被给予的营养制剂数量可以相应地降低。
用下面的非限制性实施例进一步对本发明进行说明。
实施例1
下面给出了本发明儿科营养制剂组成的一个实例。给出这种组成仅仅是为了进行说明。
该配方具有下面的组成(每100g粉末):总脂肪18.3g,总蛋白13.9g,总碳水化合物59.2g,富含AA的油(真菌的)0.2g,富含DHA的油(低EPA鱼油)0.2g,阿拉伯胶/FOS/菊粉(51%/34%/15%)12g,副干酪乳杆菌CNCM I-2116(Nestle,喷雾干燥的粉末,10E12cfu/g)0.1g,长双岐杆菌BB536(Morinaga,喷雾干燥的粉末,5×10E12cfu/g)0.1g,钠222mg,钾500mg,氯370mg,磷278mg,钙417mg,镁53mg,锰231μg,维生素A 680IU,维生素D 180IU,维生素E 6.8IU,维生素C 36mg,维生素K118μg,维生素B1 0.27mg,维生素B2 0.36mg,维生素B6 0.36mg,烟酸2.7mg,叶酸91μg,泛酸1.4mg,维生素B120.68μg,生物素6.8μg,胆碱110mg,牛磺酸36mg,肉毒碱18mg,铁4.5mg,碘36μg,铜0.36mg和锌4.5mg。
通过将221g粉末与779ml水混合来将该配方重构,从而获得1L即可饮用的制剂。可以对上述组成进行改变以适应关于特定成分数量的国家官方指令。可以根据年龄以足量加入其它痕量元素(例如硒、铬、钼、氟)。
实施例2
下面的实验证明了对用本发明的营养制剂、添加了本发明组合物的单个组分的营养制剂以及未添加的营养制剂饲养的应激新生大鼠的影响。
动物
初次怀孕的雌性Long-Evans Hooded大鼠购自Janvier(法国),在其妊娠第10和11天时抵达动物护理设施。将其在恒定的温度和湿度下单独饲养至分娩,并且给其维持12:12的黑暗:光照循环。使其自由进食进水。在该方案进行期间维持饲养条件不变。在分娩后一天(产后第2天-PND2),将母鼠从其产仔的笼子中取出并确定幼仔的性别。将标准化的一窝8只雄性幼仔随机分配进行抚养。
新生儿应激
将母鼠以及其幼仔分配到两种饲养条件之一中:1)母体分离组,在PND2至14,每天使幼仔与母亲分离180分钟(MS),或2)触摸对照,每天进行操作(称重和15分钟触摸),但是不进行母体分离(NS)。在9am,将母鼠从其居住的笼子中取出并在3小时的分离期间(MS母鼠)或者在15分钟的操作期间(NS母鼠)将其保留在等候笼中。将各MS幼仔从其窝里取出、称重并作为一组将其放在毗邻房间中隔离的笼子中。将该隔离的笼子保持在32.0±0.5℃下。在分离期结束时,将幼仔放回到其居住的笼子中并在将其与养育其的母亲放到一起之前,将其在赃褥草上滚动。类似地对得自NS组的幼仔进行处理,但不进行3小时的分离,而是温和地对其触摸15分钟。有5组MS幼仔和1组NS幼仔,各组由8只幼仔组成。
一周一次地用清洁的褥草代替其居住的笼子中50%的赃褥草。
实验方案
5个MS组中的所有幼仔在PND 15时都完全与养育其的母亲分离,断奶,进食对照饮食或添加饮食1至4之一。使得自这些组各组的幼仔居住在一起(5只动物/笼)。NS组仍然与其母亲生活在一起直至PND 21。从PND15至21,每天监测所有幼仔的体重。在PND 21,将NS组的幼仔断奶,使其进食对照饮食。然后,从那时起直至PND 36该研究结束时,所有的幼仔都独立居住。从PND 15至PND 36,MS组的幼仔继续接受其从断奶时开始食用的饮食。每天早晨将其食物代之以新鲜批次并且所有的幼仔都随意进食。
饮食
从PND 15直至PND 36,用营养上进行了调整的半合成饮食(改良的AIN 93 G)对MS组的动物进行饲养,该饮食的组成如下面的表1中所示。进行了添加的饮食包含一种或多种下面的功能性组分:副干酪乳杆菌CNCM I-2116(4×1010 cfu(位于0.8ml spent培养基中)/100g饮食);0.4g/100g饮食菊粉(Orafti SA,比利时),3.6g/100g饮食GOS(Borculo Domo Ingredients,荷兰),2g/100g饮食花生四烯酸(USA)和2g/100g饮食二十二碳六烯酸(USA)。对照饮食在spent培养基中包含代替益生菌的新鲜MRS、乳糖(Fluka,61340)和代替益生元的数量增加的麦芽糖糊精(Glucidex D 12,Roquette Freres,法国)和代替二十二碳六烯酸和花生四烯酸的数量增加的可可脂和玉米油。同样,仅包含本发明组合物的一种成分的添加饮食包含适宜的安慰剂成分。
表1.饮食的组成
成分 | 对照 | 添加1 | 添加2 | 添加3 | 添加4 |
K-酪蛋白酸盐(g) | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 |
玉米淀粉(g) | 32.95 | 32.95 | 32.95 | 32.95 | 32.95 |
麦芽糖糊精(g) | 20.74 | 12.58 | 12.58 | 12.58 | 12.58 |
蔗糖(g) | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
乳糖(g) | 4.26 | ||||
菊粉HP(g) | 0.42 | 0.42 | |||
Vivinal GOS 10(g) | 12.00 | 12.00 | |||
脂肪混合物(g)(见下) | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
矿物质混合物(AIN-93-G) | 3.50 | 3.50 | 3.50 | 3.50 | 3.50 |
维生素混合物(AIN-93-VX) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
L-半胱氨酸 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 |
胆碱酒石酸氢盐DAB 10 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
MRS(ml) | 0.80 | 0.80 | 0.80 | ||
副干酪乳杆菌CNCMI-2116(ml) | 0.80 | 0.80 |
表2.脂肪混合物
成分(g/100g脂肪混合物) | 对照 | 添加1 | 添加2 | 添加3 | 添加4 |
豆油 | 25.12 | 26.44 | 26.44 | 25.12 | 25.12 |
Trisun 80 | 2.59 | 2.59 | |||
可可脂 | 30.26 | 27.12 | 27.12 | 30.26 | 30.26 |
玉米油 | 44.63 | 34.22 | 34.22 | 44.63 | 44.63 |
ARASCO | 4.70 | 4.70 | |||
DHASCO | 4.93 | 4.93 |
统计学
将数据表示为均值±SEM的形式。在各组中检查数据的常态和同方差性。在每一个年龄,都用单侧ANOVA然后用Fisher最小显著差异(LSD)对得自PND 15至PND21的体重、体重指数和脂肪垫重量数据进行比较以对组间差异进行评估。通过重复测量ANOVA和LSD来对得自PND21的体重和摄取量曲线进行比较以对组间差异进行评估。
结果
结果如附图所示。从图1可以看出,NS组的幼仔在PND 15至21期间继续正常生长,而5个MS组的体重都降低直至PND 17,然后恢复生长,其中用本发明组合物(添加饮食1)饲养的组表现出最有效的追赶生长。从PND 21至36,接受本发明组合物的组的这种趋势加速,在PND 36时达到与NS组十分相似的重量(图2)。相比而言,可以看到用对照饮食(即与NS组相同的饮食)饲养的MS组在PND 36时体重显著降低。从图2还可以看出,接受添加饮食4(仅益生菌)的MS组最后也达到了与对照NS组相当的重量。由图3可以看出其原因,图3表明,这一组的摄食量从PND 21至36始终高于所有其它组。但是,这种较高的热量摄取似乎不能直接转化成生长。相比而言,接受添加饮食1的MS组的摄食量比接受添加饮食4的MS组低并且与包括接受对照饮食在内的其它组的摄食量相当。
此外,从图4和5可以看出,接受添加饮食1的MS组表现出的追赶生长并不伴有体重指数或总机体脂肪质量的增加,因为这些参数与未应激组的参数相当。我们得出的结论是,包含本发明成分的组合的营养制剂可有效促进其生长由于生理或心理应激曾被阻滞的幼年哺乳动物的追赶生长并且该组合是协同性的,因为单独给予的成分的作用总和低于该组合的作用。此外,所述追赶生长并不伴有体重指数的不成比例的增加,因此,其不会增加以后肥胖的风险。
Claims (24)
1.n3长链多不饱和脂肪酸、益生纤维和益生菌株用于制备用于促进患病和恢复期幼年哺乳动物的追赶生长的营养制剂或药物的应用,其中所述制剂或药物包含含有脂肪酸的脂类源并且n3长链多不饱和脂肪酸的存在量为脂类源中脂肪酸的至少0.01%、所述益生纤维的存在量为0.0001至0.05g/g制剂并且所述益生菌株的存在量为103-1011cfu/g制剂。
2.权利要求1所述的应用,其中所述营养制剂或药物还包含n6LC-PUFA。
3.权利要求2所述的应用,其中所述n6LC-PUFA的存在量为脂类源中脂肪酸的至少0.01%。
4.权利要求1至3中任意一项所述的应用,其中所述益生菌株是乳酸杆菌。
5.权利要求4所述的应用,其中所述乳酸杆菌是副干酪乳杆菌CNCMI-2116。
6.权利要求4所述的应用,其中所述乳酸杆菌是鼠李糖乳酸杆菌ATCC53103。
7.权利要求1至3中任意一项所述的应用,其中所述益生菌株是乳双歧杆菌CNCM I-3446。
8.权利要求1至3中任意一项所述的应用,其中所述益生纤维的存在量为0.02至0.05g/g制剂。
9.权利要求1至3中任意一项所述的应用,其中所述益生纤维是低聚果糖、菊粉、低聚半乳糖、阿拉伯胶或其混合物。
10.权利要求9所述的应用,其中所述益生纤维是40至60%阿拉伯胶、10至20%菊粉和30至40%低聚果糖的混合物。
11.权利要求5所述的应用,其中所述益生纤维的存在量为0.02至0.05g/g制剂。
12.权利要求5所述的应用,其中所述益生纤维是低聚果糖、菊粉、低聚半乳糖、阿拉伯胶或其混合物。
13.权利要求12所述的应用,其中所述益生纤维是40至60%阿拉伯胶、10至20%菊粉和30至40%低聚果糖的混合物。
14.权利要求6所述的应用,其中所述益生纤维的存在量为0.02至0.05g/g制剂。
15.权利要求6所述的应用,其中所述益生纤维是低聚果糖、菊粉、低聚半乳糖、阿拉伯胶或其混合物。
16.权利要求15所述的应用,其中所述益生纤维是40至60%阿拉伯胶、10至20%菊粉和30至40%低聚果糖的混合物。
17.权利要求6所述的应用,其中所述的益生纤维是低聚唾液糖。
18.权利要求7所述的应用,其中所述益生纤维的存在量为0.02至0.05g/g制剂。
19.权利要求7所述的应用,其中所述益生纤维是低聚果糖、菊粉、低聚半乳糖、阿拉伯胶或其混合物。
20.权利要求19所述的应用,其中所述益生纤维是40至60%阿拉伯胶、10至20%菊粉和30至40%低聚果糖的混合物。
21.权利要求7所述的应用,其中所述的益生纤维是低聚唾液糖。
22.权利要求2至3中任意一项所述的应用,其中n6LC-PUFA:n3LC-PUFA的比例为1∶2至8∶1。
23.权利要求1至3中任意一项所述的应用,其中所述n3LC-PUFA是二十二碳六烯酸。
24.权利要求2至3中任意一项所述的应用,其中所述n6LC-PUFA是花生四烯酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05109248.4 | 2005-10-05 | ||
EP05109248 | 2005-10-05 | ||
PCT/EP2006/066970 WO2007039596A1 (en) | 2005-10-05 | 2006-10-02 | Nutritional formulation for promoting catch-up growth |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101299934A CN101299934A (zh) | 2008-11-05 |
CN101299934B true CN101299934B (zh) | 2012-08-08 |
Family
ID=35709026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800413205A Expired - Fee Related CN101299934B (zh) | 2005-10-05 | 2006-10-02 | 用于促进追赶生长的营养制剂 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9144250B2 (zh) |
EP (1) | EP1940248B1 (zh) |
CN (1) | CN101299934B (zh) |
AT (1) | ATE451845T1 (zh) |
AU (1) | AU2006298720C1 (zh) |
BR (1) | BRPI0616899A2 (zh) |
CA (1) | CA2624921C (zh) |
DE (1) | DE602006011195D1 (zh) |
ES (1) | ES2334943T3 (zh) |
MY (1) | MY143654A (zh) |
PL (1) | PL1940248T3 (zh) |
PT (1) | PT1940248E (zh) |
RU (1) | RU2445360C2 (zh) |
TW (1) | TWI404508B (zh) |
WO (1) | WO2007039596A1 (zh) |
ZA (1) | ZA200803769B (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075934B2 (en) | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
US20080254166A1 (en) * | 2007-01-25 | 2008-10-16 | Potter Susan M | Food Additives Containing Combinations of Prebiotics and Probiotics |
JP2009102292A (ja) * | 2007-04-27 | 2009-05-14 | Chiba Prefecture | ストレス抑制剤 |
PL2190304T3 (pl) | 2007-09-17 | 2012-04-30 | Nutricia Nv | Preparat odżywczy o wysokiej wartości energetycznej |
WO2009037136A2 (en) * | 2007-09-21 | 2009-03-26 | Kerry Group Services International Limited | A probiotic composition |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
JP5268916B2 (ja) * | 2008-03-27 | 2013-08-21 | 森永乳業株式会社 | 酸性乳酸菌飲料、酸性乳酸菌飲料の製造方法、およびビフィズス菌の生残性改善方法 |
EP2110028A1 (en) * | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
US20100074870A1 (en) * | 2008-09-19 | 2010-03-25 | Bristol-Myers Squibb Company | Probiotic infant products |
CA2755860A1 (en) | 2009-04-03 | 2010-10-07 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
MX338680B (es) * | 2009-05-11 | 2016-04-27 | Nestec Sa | Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes. |
WO2010134800A1 (en) * | 2009-05-19 | 2010-11-25 | N.V. Nutricia | Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution |
EP2258217A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Children |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
EP2258218A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
US20120121562A1 (en) * | 2009-07-31 | 2012-05-17 | Nestec S.A. | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients |
JP6006117B2 (ja) | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
IT1405395B1 (it) * | 2010-08-05 | 2014-01-10 | Proge Farm Srl | Composizioni di probiotici e oli e loro uso. |
WO2012050434A1 (en) * | 2010-10-15 | 2012-04-19 | N.V. Nutricia | Dairy based smoothie for stimulating growth in children |
US9375028B2 (en) * | 2010-12-09 | 2016-06-28 | Mead Johnson Nutrition Company | Compositions and methods for nutrient delivery |
US20130095204A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Nutritional phytonutrient compositions |
ES2693519T3 (es) | 2013-11-01 | 2018-12-12 | N.V. Nutricia | Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación |
CA2942555A1 (en) | 2014-03-26 | 2015-10-01 | Abbott Laboratories | Nutritional supplement powder |
WO2017064304A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
CN108697139A (zh) | 2016-02-29 | 2018-10-23 | 雅培制药有限公司 | 营养补充粉 |
CN108882745B (zh) * | 2016-03-10 | 2023-08-18 | 花臣有限公司 | 脂质组合物及其用途 |
AU2017373837B2 (en) | 2016-12-09 | 2022-07-14 | N.V. Nutricia | Nutritional composition for improving cell membranes |
JP2023515187A (ja) * | 2020-02-27 | 2023-04-12 | アボット・ラボラトリーズ | 骨の健康を改善する方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660065A (zh) | 1997-03-27 | 2005-08-31 | 布里斯托尔-迈尔斯斯奎布公司 | 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途 |
US6495599B2 (en) | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
GB0308104D0 (en) | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
US8394370B2 (en) * | 2003-06-23 | 2013-03-12 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
WO2005063050A1 (en) | 2003-12-19 | 2005-07-14 | Abbott Laboratories | Method of increasing lean body mass and reducing body fat mass in infants |
-
2006
- 2006-10-02 AT AT06806927T patent/ATE451845T1/de not_active IP Right Cessation
- 2006-10-02 WO PCT/EP2006/066970 patent/WO2007039596A1/en active Application Filing
- 2006-10-02 DE DE602006011195T patent/DE602006011195D1/de active Active
- 2006-10-02 US US12/089,423 patent/US9144250B2/en not_active Expired - Fee Related
- 2006-10-02 RU RU2008117401/10A patent/RU2445360C2/ru not_active IP Right Cessation
- 2006-10-02 PT PT06806927T patent/PT1940248E/pt unknown
- 2006-10-02 CA CA2624921A patent/CA2624921C/en not_active Expired - Fee Related
- 2006-10-02 EP EP06806927A patent/EP1940248B1/en not_active Revoked
- 2006-10-02 AU AU2006298720A patent/AU2006298720C1/en not_active Ceased
- 2006-10-02 CN CN2006800413205A patent/CN101299934B/zh not_active Expired - Fee Related
- 2006-10-02 BR BRPI0616899-0A patent/BRPI0616899A2/pt not_active IP Right Cessation
- 2006-10-02 ES ES06806927T patent/ES2334943T3/es active Active
- 2006-10-02 PL PL06806927T patent/PL1940248T3/pl unknown
- 2006-10-05 TW TW095137247A patent/TWI404508B/zh not_active IP Right Cessation
- 2006-10-06 MY MYPI20080980A patent/MY143654A/en unknown
-
2008
- 2008-04-30 ZA ZA200803769A patent/ZA200803769B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
Also Published As
Publication number | Publication date |
---|---|
AU2006298720B2 (en) | 2012-07-19 |
US9144250B2 (en) | 2015-09-29 |
MY143654A (en) | 2011-06-30 |
CA2624921C (en) | 2012-07-10 |
US20080254012A1 (en) | 2008-10-16 |
TW200803760A (en) | 2008-01-16 |
EP1940248B1 (en) | 2009-12-16 |
ATE451845T1 (de) | 2010-01-15 |
TWI404508B (zh) | 2013-08-11 |
RU2008117401A (ru) | 2009-11-10 |
PL1940248T3 (pl) | 2010-05-31 |
DE602006011195D1 (de) | 2010-01-28 |
AU2006298720C1 (en) | 2013-03-14 |
ZA200803769B (en) | 2009-07-29 |
EP1940248A1 (en) | 2008-07-09 |
PT1940248E (pt) | 2010-01-26 |
AU2006298720A1 (en) | 2007-04-12 |
CA2624921A1 (en) | 2007-04-12 |
ES2334943T3 (es) | 2010-03-17 |
WO2007039596A1 (en) | 2007-04-12 |
RU2445360C2 (ru) | 2012-03-20 |
CN101299934A (zh) | 2008-11-05 |
BRPI0616899A2 (pt) | 2011-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101299934B (zh) | 用于促进追赶生长的营养制剂 | |
EP1638416B1 (en) | Use of a nutritional formula for optimal gut barrier function | |
TWI421034B (zh) | 營養組合物 | |
CN1889856B (zh) | 对抗化疗法和放射疗法的副作用的营养组合物 | |
RU2491080C2 (ru) | Снижение риска диареи | |
US20120107279A1 (en) | Prevention and treatment of rotavirus diarrhoea | |
TW200946033A (en) | Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation | |
CN105722514A (zh) | 用于预防或治疗剖腹产婴儿或幼儿的坏死性小肠结肠炎的组合物 | |
TW201029583A (en) | A nutritional composition comprising probiotics and improving sleep patterns | |
CN103889239A (zh) | 用于促进肠血管生成和营养吸收和经肠喂养耐受性和/或预防和/或治疗肠炎、和/或肠损伤和手术后恢复的组合物 | |
CN102186493A (zh) | 促进健康发育与成长的营养组合物 | |
RU2685187C2 (ru) | Жидкая композиция обогатителя молока с относительно высоким содержанием липидов | |
BR112021005316A2 (pt) | combinação de probióticos para o tratamento de distúrbios gastrointestinais relacionados à inflamação | |
CN113660941A (zh) | 用于治疗变态反应性疾病的益生菌组合 | |
CN107668721A (zh) | 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途 | |
KR20220107011A (ko) | 임산부의 미생물총을 개선하기 위한 hmo의 혼합물 | |
RU2789158C2 (ru) | Композиции, содержащие по меньшей мере один n-ацетилированный и по меньшей мере один фукозилированный олигосахарид, для применения в активации переваривающей способности у младенцев и детей младшего возраста | |
CN116981463A (zh) | 人乳低聚糖 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 Termination date: 20161002 |
|
CF01 | Termination of patent right due to non-payment of annual fee |